You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

Details for New Drug Application (NDA): 207648


✉ Email this page to a colleague

« Back to Dashboard


NDA 207648 describes SMOFLIPID 20%, which is a drug marketed by Fresenius Kabi Usa and is included in one NDA. It is available from one supplier. Additional details are available on the SMOFLIPID 20% profile page.

The generic ingredient in SMOFLIPID 20% is fish oil; medium chain triglycerides; olive oil; soybean oil. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fish oil; medium chain triglycerides; olive oil; soybean oil profile page.
Summary for 207648
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 207648
Generic Entry Date for 207648*:
Constraining patent/regulatory exclusivity:
NEW PATIENT POPULATION
Dosage:
EMULSION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 207648
Suppliers and Packaging for NDA: 207648
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SMOFLIPID 20% fish oil; medium chain triglycerides; olive oil; soybean oil EMULSION;INTRAVENOUS 207648 NDA Fresenius Kabi USA, LLC 63323-820 63323-820-00 10 BAG in 1 CASE (63323-820-00) / 100 mL in 1 BAG (63323-820-01)
SMOFLIPID 20% fish oil; medium chain triglycerides; olive oil; soybean oil EMULSION;INTRAVENOUS 207648 NDA Fresenius Kabi USA, LLC 63323-820 63323-820-10 6 BAG in 1 CASE (63323-820-10) / 1000 mL in 1 BAG (63323-820-05)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:EMULSION;INTRAVENOUSStrength3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (100ML)
Approval Date:Jul 13, 2016TE:RLD:Yes
Regulatory Exclusivity Expiration:Mar 22, 2025
Regulatory Exclusivity Use:NEW PATIENT POPULATION

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:EMULSION;INTRAVENOUSStrength3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (250ML)
Approval Date:Jul 13, 2016TE:RLD:Yes
Regulatory Exclusivity Expiration:Mar 22, 2025
Regulatory Exclusivity Use:NEW PATIENT POPULATION

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:EMULSION;INTRAVENOUSStrength3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (500ML)
Approval Date:Jul 13, 2016TE:RLD:Yes
Regulatory Exclusivity Expiration:Mar 22, 2025
Regulatory Exclusivity Use:NEW PATIENT POPULATION

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.